#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should be aware that cannabis use is associated with increased stroke risk, which necessitates screening patients about cannabis consumption during stroke risk assessments and counseling patients about this cardiovascular danger. Understanding this association helps practitioners contextualize sudden neurological symptoms in cannabis users and informs shared decision-making conversations about substance use harm reduction.
This study by Ritson and colleagues demonstrates that cannabis use, along with cocaine and amphetamine use, is associated with significantly increased odds of stroke in users. The research contributes to growing evidence that cannabis is not a benign substance and carries cardiovascular risks that clinicians should consider when evaluating stroke risk in patients, particularly younger individuals who may not have traditional vascular risk factors. The association between cannabis and stroke has important implications for patient counseling, risk stratification, and clinical decision-making around cannabis use in populations with existing cardiovascular disease or stroke risk factors. Understanding this relationship helps clinicians better inform patients about the potential cerebrovascular consequences of cannabis use and supports more comprehensive risk assessment during initial and ongoing care. Clinicians should incorporate cannabis use history into stroke risk evaluation and discuss cardiovascular complications when counseling patients considering or actively using cannabis.
“We need to separate the cannabis signal from stimulant-induced stroke risk in these studies, because the mechanisms are fundamentally different. Cannabis users in this population are often poly-substance users, and it’s the sympathomimetic drugs like cocaine and amphetamines that reliably cause acute hypertension and vasospasm, whereas cannabis’s cardiovascular effects are much more modest and idiosyncratic. The clinical takeaway for my patients is straightforward: if you have stroke risk factors, stimulants are far more dangerous than cannabis, but both warrant a careful conversation about your individual vascular health.”
💉 Clinicians should be aware that cannabis use joins cocaine and amphetamines as a substance associated with increased stroke risk, a finding that warrants inclusion in stroke risk assessment and patient counseling. However, the association between cannabis and stroke remains incompletely understood, with potential confounders such as concurrent tobacco use, underlying cardiovascular disease, and the distinction between occasional and heavy use not always clearly delineated in available literature. The route of administration (smoking versus other methods), cannabis potency and cannabinoid profile, and individual genetic susceptibility may all modulate stroke risk in ways that current epidemiologic studies cannot fully capture. Given the increasing prevalence of cannabis use in many populations and its legal status in some jurisdictions, clinicians should routinely ask about cannabis consumption when taking vascular histories and counsel patients, particularly younger individuals, about this potential serious adverse effect. When discussing stroke prevention with cannabis users, individualized risk-benefit conversations that acknowledge both
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: